Skip to Content
Bookmark and Share

COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC:
Get the latest research information from NIH:


Timing of Alcohol and Other Drug Use

Christopher S. Martin, Ph.D.

Christopher S. Martin, Ph.D., is an associate professor of psychiatry and psychology at the Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

Many Americans who drink alcohol are polydrug users—that is, they also use other psychoactive drugs, such as nicotine, pharmaceuticals, cannabis, and other illicit substances. Polydrug use is a general term that describes a wide variety of substance use behaviors. Different types of polydrug use can be described with regard to the timing of the ingestion of multiple substances. Concurrent polydrug use (CPU) is the use of two or more substances within a given time period, such as a month or a year. Simultaneous polydrug use (SPU) is the use of two or more substances in combination (i.e., at the same time or in temporal proximity) (Grant and Harford 1990a). Thus, although all simultaneous polydrug users are, by definition, concurrent users, concurrent users may or may not be simultaneous users. This article describes the functions of SPU for substance users, as well as the measurement, prevalence, patterns, and consequences of SPU.

Functions of SPU

SPU varies according to the user’s intentions regarding the pharmacological and subjective effects of mixing drugs (Ives and Ghelani 2006; Schensul et al. 2005). Although some SPU may reflect an indiscriminate or haphazard pattern of use, the vast majority of users report a great deal of intentionality regarding their choice of drug combinations (Wibberley and Price 2000). Many experienced substance users demonstrate substantial knowledge of the pharmacology of various drugs and how to combine them to produce certain desired types of intoxication (Merchant and Macdonald 1994; Uys and Niesink 2005).

People often use multiple substances at the same time to produce additive or interactive (i.e., synergistic) subjective drug effects (Wibberley and Price 2000). Perceptions of enhanced or potentiated subjective effects among those who engage in SPU have a pharmacologic basis. Pharmacological evidence exists for the synergistic effects of some drug combinations, suchas alcohol and certain classes of sedatives. Another example is the production of the psychoactive compound cocaethylene in those who use alcohol in combination with cocaine (Jatlow et al. 1991). In many cases, more research is needed to determine whether different drug combinations have additive or interactive effects on intoxication and impairment.

Some people also use one drug to reduce or offset some or all of the effects of another substance. In such cases, the user often staggers the timing of ingesting different substances. For example, sedatives may be used to reduce anxiety and allow sleep subsequent to a cocaine binge. A time lag is not always necessary, however, to have one substance counteract or offset the effects of another. For example, some people who are not regular smokers nevertheless smoke while drinking alcohol. The nicotine may help them to maintain a level of alertness, which allows them to better enjoy or prolong an episode of alcohol intoxication (Istvan and Matarazzo 1984). More research is needed regarding intentionality and functionality in various patterns of SPU.

Measuring SPU

Most substance use measures do not assess combined use and, therefore, can only provide information about CPU and not SPU.1 (1 This also is true of the National Epidemiologic Survey on Alcohol and Related Conditions [NESARC].) Simultaneous use is more difficult and time consuming to measure than concurrent use (Schensul et al. 2005) and requires the assessment of the temporal proximity of multiple drug use. The specific time frame that ensures combined pharmacologic effects is difficult to determine and depends on factors such as the quantity consumed and the rate of metabolism for each substance. The timeline follow-back technique (TLFB) (Sobell and Sobell 1992) has been adapted to assess the use of alcohol and other drug classes on each of the past 30 days (e.g., Martin et al. 1996a), but this provides limited resolution regarding temporal proximity. The SPU Questionnaire (SPUQ) assesses the frequency of use of specific substances within 3 hours of each other (Martin et al. 1992). SPUQ and TLFB measures of the occurrence and frequency of different substance combinations are highly correlated (Martin et al. 1996a). Other researchers have developed questionnaires that assess particular alcohol–drug combinations (e.g., Collins et al. 1998; Grant and Harford 1990a,b; McCabe et al. 2006).

Prevalence of SPU

Alcohol with tobacco undoubtedly is the most common drug combination used in the United States, although their simultaneous use has not been directly assessed in large epidemiological studies. Using data from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC), Falk and colleagues (2006) found that 21.7 percent of adults (27.5 percent of men and 16.4 percent of women) reported the use of alcohol and nicotine in the past year. Although not measured in the NESARC, it is likely that the large majority of these individuals also used these two drugs simultaneously.

Marked increases in the combined use of alcohol and illicit drugs have occurred over the past 40 years, although little research has focused on the prevalence of specific patterns of SPU. A consistent finding is that SPU is more common in males and among teens and young adults. Marijuana is by far the most common illicit drug used in combination with alcoholin the United States. A national survey conducted in the early 1980s of people ages 12 and older showed that 11 percent of males and 4 percent of females reported combined (i.e., simultaneous) alcohol and marijuana use in the past month. Among 18- to 25-year-olds, the percentages were 24 percent for men and 12 percent for women (Norton and Colliver 1988). Using a representative sample of 12th graders studied in the 1990s, Collins and colleagues (1998) reported that 27.6 percent had engaged in combined alcohol and marijuana use in the past year. National survey data collected in 2000 show that 7 percent of those ages 18 and older (8.5 percent of men and 5.5 percent of women) reported past-year simultaneous use of alcohol and marijuana (Midanik et al. 2007).

The prevalence of other alcohol and drug combinations is lower but substantial. Using a representative 1985 adult sample, Grant and Harford (1990a, b) reported past-year rates of combined use of 1.6 percent for alcohol with sedatives, 3.3 percent for alcohol with tranquilizers, and for 4.7 percent for alcohol with cocaine. National survey data from 2000 showed lower rates, with 1.7 percent of adults reporting the combined use of alcohol with an illicit drug other than marijuana in the past year (Midanik et al. 2007). Among 12th-graders in the 1990s, Collinsand colleagues (1998) found past-year rates of 2.3 percent for alcohol with sedatives, 6.7 percent for alcohol with stimulants, 5.3 percent for cocaine with other drugs, and 9.9 percent for any substance combination that included an illicit drug other than marijuana. McCabe and colleagues (2006) found that 6.9 percent of a college student sample reported the use of alcohol in combination with nonprescribed pharmaceutical drugs in the past year.

Patterns of SPU

Those few studies that have assessed the temporal proximity of polydrug use have consistently shown that the majority of concurrent polydrug users also report simultaneous use. This has been found in general population surveys (Grant and Harford 1990; Midanik et al. 2007; Norton and Colliver 1988), among high school and college students (Collins et al. 1998; Martin et al. 1992), among clubgoers (Lankenau and Clatts 2005), and in treatment samples of adults (Martin et al. 1996a; Petry 2001) and adolescents (Martin et al. 1996b). There are large individual differences, however, in the frequency of simultaneous use. For example, some people report using illicit drugs only rarely while drinking, whereas others use drugs nearly every time they drink (Martin et al., 1996a).

The use of three or more substances concurrently and sometimes simultaneously is common among people in addictions treatment. In a treatment sample of adults, Martin and colleagues (1996a) found that of those who reported SPU in the past 120 days (61 percent of the sample), about 25 percent consumed alcohol and two illicit drugs in combination, with an average frequency of about once per week, and about 10 percent sometimes drank alcohol in combination with three or more illicit drugs. Similarly, about 17 percent of adolescents in addiction treatment who had an alcohol use disorder reported the use of two or more illicit drugs in combination with alcohol in the past year (Martin et al. 1996b).

SPU patterns show age-related differences (e.g., Midanik et al. 2007), regional and ethnic differences (Epstein et al. 1999, 2002), and changing trends over time. Research has highlighted extensive use of alcohol and prescription drugs among college students (McCabe et al. 2006), as well as relatively recent trends of youth and young adults using ecstasy, ketamine, and other “club drugs” in combination with alcohol and other illicit substances (e.g., Lankenau and Clatts 2005; Pedersen and Skrondal 1999). The field needs to continue its surveillance efforts to understand new emerging patterns of SPU, especially among youth.

Consequences of SPU

SPU can have particularly dangerous consequences because AOD combinations can have additive or interactive effects on acute intoxication and impairment. The majority of deaths attributed to heroin overdose involve significant levels of other drugs such as alcohol or benzodiazepines; opiate levels appear to be similar in both fatal and nonfatal overdoses (Darke and Zador 1996). Similarly, about two-thirds of oxycodone-related deaths were found to involve the use of alcohol and/or other drugs (Cone et al. 2003, 2004). Finally, fatalities and injuries reported to be “alcohol-related” often involve other drug use (Gossop 2001).

Aside from the acute effects associated with intoxication and impairment, little research has examined SPU in relation to health and psychosocial functioning. Although alcohol and tobacco have additive and occasionally interactive effects on health outcomes, such as cardiovascular disease and cancer (Mukamal 2006; Pelucchi et al. 2006), it is unclear whether such effects are related specifically to simultaneous use. Earleywine and Newcomb (1997) found that in a community study of young adults, those who engaged in certain patterns of SPU had more subsequent physical health problems and psychological distress than those who engaged only in concurrent use. Midanik and colleagues (2007) found that compared with concurrent use only, the simultaneous use of alcohol with marijuana, as well as alcohol with other drugs, was associated with increased social problems. Although more research is needed to understand the consequences of SPU, there is little doubt that such behavior represents a major public health problem.

Financial Disclosure

The author declares that he has no competing financial interests.


Collins, R.L.; Ellickson, P.L.; and Bell, R.M. Simultaneous polydrug use among teens: Prevalence and predictors. Journal of Substance Abuse 10:233–253, 1998. PMID: 10689657

Cone, E.J.; Fant, R.V.; Rohay, J.M. et al. Oxycodone involvement in drug abuse deaths: A DAWN-based classification scheme applied to an oxycodone postmortem database covering over 1,000 cases. Journal of Analytical Toxicology 27:57–67, 2003. PMID: 12669998

Cone, E.J.; Fant, R.V.; Rohay, J.M. et al. Oxycodone involvement in drug-related deaths: II. Evidence for toxic multiple drug-drug interaction. Journal of Analytical Toxicology 28:217–225, 2004. PMID: 15516322

Darke, S., and Zador, D. Fatal heroin “overdose:” A review. Addiction 91:1765–1772, 1996. PMID: 8997759

Earleywine, M., and Newcomb, M.D. Concurrent versus simultaneous polydrug use: Prevalence, correlates, discriminant validity, and prospective effects on health outcomes. Experimental and Clinical Psychopharmacology 5:353–364, 1997. PMID: 9386962

Epstein, J.A.; Botvin, G.; Griffin, K.; and Diaz, T. Role of ethnicity and gender in polydrug use among a longitudinal sample of inner-city adolescents. Journal of Alcohol and Drug Education 45:1–12, 1999.

Epstein, J.A.; Botvin, G.; and Diaz, T. Gateway polydrug use among Puerto Rican and Dominican adolescents residing in New York City: The moderating role of gender. Journal of Child and Adolescent Substance Abuse 12: 33–46, 2002.

Falk, D.E.; Yi, H.-Y.; and Hiller-Sturmhöfel, S. An epidemiologic analysis of co-occuring alcohol and tobacco use and disorders: Findings from the National Epidemiological Survey on Alcohol and Related Conditions. Alcohol Research & Health 29:162–171, 2006. PMID: 17373404

Gossop, M. A web of dependence. Addiction 96:677–678, 2001. PMID: 11331024

Grant, B.F., and Harford, T.C. Concurrent and simultaneous use of alcohol with sedatives and tranquilizers: Results of a nation survey. Journal of Substance Abuse 2:1–14, 1990a. PMID: 1983776

Grant, B.F., and Harford, T.C. Concurrent and simultaneous use of alcohol with cocaine: Results of a nation survey. Drug and Alcohol Dependence 25: 97–104, 1990b. PMID: 2323315

Ives, R., and Ghelani, P. Polydrug use (the use of drugs in combination): A brief review. Drugs: Education, Prevention and Policy 13:225–232, 2006.

Jatlow, P.; Elsworth, J.D.; Bradberry, C.W.; et al. Cocaethylene: A Neuropharmacologically active molecule associated with concurrent cocaine-ethanol ingestion. Life Sciences 48(18):1787–1794, 1991. PMID: 2020260

Lankenau, S.E., and Clatts, M.C. Patterns of polydrug use among ketamine injectors in New York City. Substance Use and Misuse 40:1381–1397, 2005. PMID: 16048823

Martin, C.; Clifford, P.; and Clapper, R. Simultaneous and concurrent use of alcohol, tobacco, marijuana, and hallucinogens in first year college students. Journal of Substance Abuse 4:319–326, 1992.

Martin, C.; Clifford, P.; Maisto, S. et al. Polydrug use in an inpatient treatment sample of problem drinkers. Alcoholism: Clinical and Experimental Research 20:413–417, 1996a. PMID: 8727229

Martin, C.; Kaczynski, N.; Maisto, S.; and Tarter, R. Polydrug use in adolescent drinkers with and without DSM-IV alcohol abuse and dependence. Alcoholism: Clinical and Experimental Research 20:1099–1108, 1996b. PMID: 8892534

McCabe, S.E.; Cranford, J.A.; Morales, M.; and Young, A. Simultaneous and concurrent polydrug use of alcohol and prescription drugs: Prevalence, correlates, and consequences. Journal of Studies on Alcohol 67:529–537, 2006. PMID 16736072

Merchant, J. and Macdonald, R. Youth and rave culture: Ecstacy and health. Youth Policy 45:16–37, 1994.

Midanik, L.T.; Tam, T.W.; and Weisner, C. Concurrent and simultaneous drug and alcohol use: Results of the 2000 National Alcohol Survey. Drug and Alcohol Dependence 90:72–80, 2007.

Mukamal, K.J. The effects of smoking and drinking on cardiovascular disease and risk factors. Alcohol Research & Health 29:199–202, 2006. PMID: 17373409

Norton, R., and Colliver, J. Prevalence and patterns of combined alcohol and marijuana use. Journal of Studies on Alcohol 49:378–380, 1988. PMID: 3172788

Pedersen, W., and Skrondal, A. Ecstacy and new patterns of drug use: A normal population study. Addiction 94:1695–1706, 1999. PMID: 10892008

Pelucchi, C.; Gallus, S.; Garavello, W.; et al. Cancer risk associated with alcohol and tobacco use: Focus on upper aero-digestive tract and liver. Alcohol Research & Health 29:193–198, 2006. PMID: 17373408

Schensul, J.J.; Convey, M.; and Burkholder, G. Challenges in measuring concurrency, agency and intentionality in polydrug research. Addictive Behaviors 30: 571–574, 2005. PMID: 15718073

Sobell, L., and Sobell, M. Timeline follow-back: A technique for assessing self-reported alcohol consumption. In Litten, R., and Allen, J., Eds. Measuring Alcohol Consumption. Clifton, N.J.: Humana Press, 1992, pp. 41–72.

Uys, J.D.K., and Niesink, J.M. Pharmacological aspects of the combined use of 3,4-methylenedioxymethampetamine (MDMA, ecstacy) and gamma-hydroxybutyric acid (GHB): A review of the literature. Drug and Alcohol Review 24:359–368, 2005. PMID: 16234132

Wibberley, C., and Price, J. Patterns of psycho-stimulant drug use amongst “social/operational users:” Implications for services. Addiction Research 8: 95–111, 2000.